Sutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have been assigned a consensus rating of “Moderate Buy” from the eight analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $11.13.

A number of equities analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Sutro Biopharma in a report on Monday, November 18th. Wedbush restated an “outperform” rating and issued a $8.00 price objective on shares of Sutro Biopharma in a research note on Tuesday, December 10th. JMP Securities reiterated a “market outperform” rating and set a $17.00 target price on shares of Sutro Biopharma in a research note on Wednesday, December 11th. Finally, Wells Fargo & Company lowered their price target on Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 11th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Bank of Montreal Can acquired a new stake in Sutro Biopharma in the third quarter valued at $2,852,000. BNP Paribas Financial Markets lifted its stake in shares of Sutro Biopharma by 1,195.1% in the third quarter. BNP Paribas Financial Markets now owns 82,524 shares of the company’s stock valued at $286,000 after purchasing an additional 76,152 shares during the period. Jane Street Group LLC boosted its holdings in Sutro Biopharma by 30.7% during the third quarter. Jane Street Group LLC now owns 108,192 shares of the company’s stock worth $374,000 after buying an additional 25,416 shares in the last quarter. Barclays PLC boosted its holdings in Sutro Biopharma by 385.3% during the third quarter. Barclays PLC now owns 273,019 shares of the company’s stock worth $944,000 after buying an additional 216,757 shares in the last quarter. Finally, State Street Corp grew its position in Sutro Biopharma by 5.2% during the third quarter. State Street Corp now owns 1,647,162 shares of the company’s stock worth $5,699,000 after buying an additional 81,855 shares during the period. 96.99% of the stock is owned by hedge funds and other institutional investors.

Sutro Biopharma Stock Down 10.1 %

STRO opened at $1.79 on Tuesday. Sutro Biopharma has a 52 week low of $1.67 and a 52 week high of $6.13. The business’s 50 day moving average is $2.05 and its two-hundred day moving average is $3.14. The firm has a market cap of $147.60 million, a price-to-earnings ratio of -1.11 and a beta of 1.15.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.